HUBB vs LEGN

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus 3. 8% for Hubbell Incorporated (HUBB). Hubbell Incorporated (HUBB) offers the better valuation at 29. 8x trailing P/E (24. 9x forward), making it the more compelling value choice. Analysts rate Legend Biotech Corporation (LEGN) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Hubbell Incorporated is actually cheaper at 24.

9x.

Over the past 5 years, Hubbell Incorporated (HUBB) delivered a total return of +161.

4%, compared to -4. 2% for Legend Biotech Corporation (LEGN). Over 10 years, the gap is even starker: HUBB returned +410. 2% versus LEGN's -24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

76β versus Hubbell Incorporated's 1. 32β — meaning HUBB is approximately 74% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Legend Biotech Corporation (LEGN) carries a lower debt/equity ratio of 41% versus 68% for Hubbell Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus 3. 8% for Hubbell Incorporated (HUBB). On earnings-per-share growth, the picture is similar: Hubbell Incorporated grew EPS 15. 1% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hubbell Incorporated (HUBB) is the more profitable company, earning 15.

2% net margin versus -28. 8% for Legend Biotech Corporation — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HUBB leads at 20. 8% versus -13. 3% for LEGN. At the gross margin level — before operating expenses — LEGN leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hubbell Incorporated (HUBB) trades at 24.

9x forward P/E versus 116. 2x for Legend Biotech Corporation — 91. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LEGN: 105. 9% to $57. 89.

In this comparison, HUBB (1.

1% yield) pays a dividend. LEGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Hubbell Incorporated (HUBB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +410. 2% 10Y return). Both have compounded well over 10 years (HUBB: +410. 2%, LEGN: -24. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HUBB (Industrials) and LEGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HUBB is a mid-cap quality compounder stock; LEGN is a small-cap high-growth stock. HUBB pays a dividend while LEGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.